Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

ClariVy Cervical IBF System Receives FDA Clearance

ClariVy Cervical IBF System: VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the FDA for the its ClariVy Cervical IBF System which is designed for use in anterior cervical discectomy with fusion (ACDF) procedures.

The ClariVy Cervical IBF System features cervical interbody fusion devices made from either PEEK Optima LT1, or PEEK Optima HA-Enhanced. PEEK Optima LT1 has been the standard for interbody devices for decades, featuring radiolucency and a modulus of elasticity close to that of natural bone. PEEK Optima HA-Enhanced has embedded Hydroxyapatite fibers to create better bony apposition to the implant.

“The ClariVy Cervical IBF System is the first in a series of differentiated interbody systems being developed by VySpine,” said Tom McLeer, CEO of VySpine. “Using new materials and creative surgeon input, we are building exceptional quality, flexibility, and pricing into all our products. This is just the next step in a series of exciting, innovative product launches scheduled for 2022.”

The ClariVy Cervical IBF System is offered in numerous footprints and heights, ranging from 4mm to 11mm and available either with or without locking screws. Additionally, the ClariVy implants are available in a range of lordosis. The ClariVy Cervical IBF System also features IBF-S implants, which have self-drilling screws to aid in anchoring the device directly to the bone. These screws are self-locking to ensure quick and easy fixation.

SourceVySpine
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy